EAU 2014 - Poster: Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase and prostate-specific antigen in patients with castration-resistant prostate cancer and symptomatic bone metastases from the phase 3 ALSYMPCA trial

STOCKHOLM, SWEDEN (UroToday.com) - Presented by D. Heinrich,¹ C. Parker,² M. Shan,³ S. Wilhelm,³ M. Wahba,³ J. Garcia-Vargas,³ C.G. O’Bryan-Tear,⁴ O. Sartor⁵ at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

¹Akershus University Hospital, Lørenskog, Norway; ²The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK; ³Bayer HealthCare, Whippany, NJ, USA; ⁴Algeta ASA, Oslo, Norway; ⁵Tulane University Cancer Center, New Orleans, LA, USA

Click HERE to read an exclusive report by a UroToday medical writer